

Express Mail Label No.: EL883817587US
Date of Deposit: October 1, 2001

Attorney Docket No. 15966-606 (Cura-106)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS : Shimkets et al.
SERIAL NUMBER : 09/715,417 EXAMINER : Not Yet Assigned
FILING DATE : November 16, 2000 ART UNIT : 1645
FOR : Novel Polypeptides and Nucleic Acids Encoding Same

BOX IDS

Assistant Commissioner for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:

1. Supplemental Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (1 page), in duplicate;
3. Copies of cited references B1-B2, C12-C14; and
4. Return Postcard.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at (617) 542-6000, Boston, Massachusetts.

The Commissioner is authorized to charge any additional fees that may be due, or to credit any overpayment, to the undersigned's account, Deposit Account No. 50-0311 Ref. No. 15966-606 (Cura-106). A duplicate copy of this transmittal letter is enclosed herewith.

Respectfully submitted,

Ivor R. Elrifi, Reg. No. 39,529
Cynthia Kozakiewicz, Reg. No. 42,764
Attorneys for the Applicant
MINTZ, LEVIN, COHN, FERRIS,
GLOVSKY and POPEO, P.C.
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: October 1, 2001

TRA 1571372v1

10-2-01
#8
TECH CENTER 1600/2900
OCT 05 2001
RECEIVED
1645

Express Mail Label No.: EL883817587US
Date of Deposit: October 1, 2001

Attorney Docket No.: 15966-606 (Cura-106)

TECH CENTER 1600/2900

RECEIVED
OCT 05 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Shimkets et al.
SERIAL NUMBER: 09/715,417 EXAMINER: Not Yet Assigned
FILING DATE: November 16, 2000 ART UNIT: 1645
FOR: Novel Polypeptides and Nucleic Acids Encoding Same

Assistant Commissioner for Patents
Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants hereby make of record the documents listed on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application, copies of which are submitted herewith. This Supplemental Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits in the above-identified case. Accordingly, no fee or certification is required. 37 C.F.R. §1.97. A copy of each of references is enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Supplemental Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

APPLICANTS: Shimkets et al.
U.S.S.N.: 09/715,417

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 15966-606 (Cura-106).

Respectfully submitted,




Ivor R. Elrifi, Reg. No. 39,529
Cynthia A. Kozakiewicz, Reg. No. 42,764
Attorneys for Applicants
c/o MINTZ, LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241

Dated: October 1, 2001

TRA 1571381v1

Express Mail No. EL883817587US
Date of Deposit: October 1, 2001



Please type a plus sign (+) in this box



Approved for use through 9/30/00. OMB 0831-0001
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

RECEIVED
Page 1 of 1

OCT 05 2001

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	09/715,417
	Filing Date	11/16/00
	First Named Inventor	Shimkets
	Group Art Unit	1645
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	15966-606 (Cura-106)

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No		
	B1	WO 95/18823	Beth Israel Hospital	July 13, 1995			
	B2	WO 98/04688	Biopharm GMBH	February 5, 1998			

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C12	Ikegawa, S. <i>et al.</i> (1996). <i>Genomics</i> 35: 590-592.
	C13	Strausberg, R. (1999). Database EMBL Entry/Acc. No. AI613267
	C14	International Search Report, issued August 20, 2001

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.